Tritent International Corp의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
AIM ImmunoTech Inc 주요 수익원은 Ampligen and Other Drugs이며, 최신 수익 발표에서 수익은 170,000입니다. 지역별로는 United States이 AIM ImmunoTech Inc의 주요 시장이며, 수익은 170,000입니다.
Tritent International Corp은 수익성이 있나요?
no, 최신 재무제표에 따르면 AIM ImmunoTech Inc의 순손실은 $0입니다.
Tritent International Corp에 부채가 있나요?
no, AIM ImmunoTech Inc의 부채는 0입니다.
Tritent International Corp의 발행 주식은 몇 주인가요?
AIM ImmunoTech Inc의 총 발행 주식은 0주입니다.
주요 통계
이전 종가
$0.0068
시가
$0.0057
일일 범위
$0.0057 - $0.0057
52주 범위
$0.004 - $0.59
거래량
5.4K
평균 거래량
1.7K
배당수익률
--
EPS(TTM)
--
시가총액
$513
TICJ란 무엇인가요?
Tritent International Corp. is an investment company, which engages in creating value through strategic investments, operational optimization, and community engagement. The company is headquartered in Toronto, Ontario. The company went IPO on 2004-12-28. The Company’s investment strategies focused on investment in strategic alliances within the real estate, energy and logistics sectors. The company focuses on acquiring controlling equity interests in potential, disruptive companies, where the Company actively contributes to growth through capital infusion, management expertise, and operational support. The firm's investment model centers on operational optimization, strategic capital deployment, and active leadership engagement. The company provides funding, as well as critical infrastructure, executive guidance, and access to networks that foster scalability and performance.